PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10381197-0	1999	Salicylate promotes myeloperoxidase-initiated LDL oxidation: antagonization by its metabolite gentisic acid.	Salicylates	0-10	myeloperoxidase	Homo sapiens	20-35	
10381197-3	1999	Taking into consideration, that monophenolic compounds are able to form phenoxyl radicals in presence of peroxidases, we have tested salicylate, in its ability to act as a prooxidant in the MPO system.	Salicylates	133-143	myeloperoxidase	Homo sapiens	190-193	
10381197-5	1999	Exposure of LDL preparations to MPO in presence of salicylate revealed that the drug could act as a catalyst of lipid oxidation in LDL.	Salicylates	51-61	myeloperoxidase	Homo sapiens	32-35	
10381197-10	1999	The results suggest that salicylate could act like tyrosine via a phenoxyl radical as a catalyst of LDL oxidative modification by MPO.	Salicylates	25-35	myeloperoxidase	Homo sapiens	130-133	
6291348-11	1982	Salicylates and arylacetic acid derivatives, such as naproxen, also decreased MPO-CL.	Salicylates	0-11	myeloperoxidase	Homo sapiens	78-81	
8006021-10	1994	Purified human myeloperoxidase and xanthine oxidase plus hypoxanthine hydroxylated salicylate to produce 2,5-dihydroxybenzoate.	Salicylates	83-93	myeloperoxidase	Homo sapiens	15-30	
34510275-6	2021	However, one exception is salicylate, a very potent inhibitor of the neutrophilic enzyme, myeloperoxidase, the inhibition of which leads to reduced production of the inflammatory mediator, hypochlorous acid, and inhibition of the inflammation associated with rheumatoid arthritis.	Salicylates	26-36	myeloperoxidase	Homo sapiens	90-105